Characterization of the thermodynamics of DNA± drug interactions is a very useful part in rational drug design. Isothermal titration calorimetry (ITC), differential scanning calorimetry (DSC) and UV melting experiments have been used to analyze the multivalent (intercalation plus minor groove) binding of the antitumor antibiotic chartreusin to DNA. Using DNA UV melting studies in the presence of the ligand and the binding enthalpy determined by ITC, we determined that the binding constant for the interaction was 3.6 Q 10 5 M ±1 at 20°C, in a solution containing 18 mM Na + . The DNA±drug interaction was enthalpy driven, with a DH b of ±7.07 kcal/mol at 20°C. Binding enthalpies were determined by ITC in the 20±35°C range and used to calculate a bindinginduced change in heat capacity (DCp) of ±391 cal/ mol K. We have obtained a detailed thermodynamic pro®le for the interaction of this multivalent drug, which makes possible a dissection of DG obs into the component free energy terms. The hydrophobic transfer of the chartreusin chromophore from the solution to the DNA intercalating site is the main contributor to the free energy of binding.
INTRODUCTION
Characterization of DNA±drug interactions requires not only knowledge of the structures of the complexes, but the free energy contributions to the interaction (1±5). The thermodynamic characterization of drug binding might be used, together with structural studies, in the development of new strategies to interfere with gene expression in living cells (6, 7) .
A thorough characterization of a suf®ciently high number of DNA±drug complexes might be needed to understand the contributors that give rise to the observed af®nity and the nature of the interactions (3) . There are a considerable number of multivalent natural DNA-binding drugs that contain an intercalating chromophore and a carbohydrate or peptide moiety that binds in the minor groove. Both functional domains are considered to serve as DNA recognition elements.
In several anthracycline antibiotics, and other DNA-binding drugs, the non-intercalating portion can form several bonds with DNA (1, 2) , thus contributing to the stability of the complex. Multivalent binding is not only important in terms of sequence speci®city but also because the exact characteristics of a carbohydrate moiety can modify some activities, such as the DNA cleavage mediated by topoisomerase II (8) . The detection and characterization of multivalent modes of binding may result in the formulation of better rules for rational drug design. Improved drug binding af®nity and the ability to discriminate larger DNA sequences may allow us to target unique sites in the genome (6, 9) .
Chartreusin is an antitumor antibiotic (10, 11) that contains the chromophore chartarin and an uncharged disaccharide moiety ( Fig. 1 ), and possesses a broad spectrum of activity against various tumors (10) . It is a well-characterized member of a wider group of coumarin-related compounds, which includes elsamicin A and the chrymutasins (12, 13) . Binding to DNA is believed to be central to the mechanism by which chartreusin exerts its antitumoral effects (11, 14, 15) . The binding sites have been mapped in regions containing CpG steps (15) . Moreover, chartreusin appears to be a strong inhibitor of topoisomerase II (16) . It can be used as a model to study multivalent intercalation, which also involves interaction through the minor groove of DNA. Here, we present a thermodynamic characterization of the binding of chartreusin to DNA, which permitted a study of how the intercalating chromophore and uncharged disaccharide moieties contribute to the strength of binding.
Despite the pharmacological interest of chartreusin and some structurally related compounds (12) , there is no experimental data on the conformation of the isolated drug or its complexes with DNA in the crystalline state. This shortcoming has been partially solved by a theoretical approach (17) , which provided us with some details about the DNA± chartreusin interaction. Besides, previous binding data on chartreusin±DNA complexes were rather dif®cult to obtain and different results were obtained that were attributable to the formulations used to analyze the binding (11) . In view of the modular nature of chartreusin, such knowledge of the multivalent binding can be used to improve the speci®city of existing compounds and to design polyintercalators that should recognize longer DNA sequences.
Therefore, we have analyzed the binding of chartreusin to DNA and thermodynamically characterized it. We use the data *To whom correspondence should be addressed. obtained from these analyses to dissect the components that act in drug binding to DNA (3) , and compare the contribution of the intercalating and disaccharide portions with the interaction.
MATERIALS AND METHODS

Materials
Chartreusin was kindly provided by Dr W.C. Krueger (The Upjohn Co., Kalamazoo, MI). A molar extinction coef®cient of 12 700 M ±1 cm ±1 at 420 nm was used to determine the free concentration of chartreusin and 7230 M ±1 cm ±1 for bound drug. Salmon testes DNA (Sigma) was sonicated, phenol extracted twice and dialyzed against 10 mM cacodylate buffer (pH 7.0) containing 8 mM NaCl and 0.1 mM EDTA ([Na + ] = 18 mM). DNA concentration, in base pairs, was determined spectrophotometrically by using a molar extinction coef®cient of 12 824 M ±1 cm ±1 at 260 nm.
Continuous variation binding analysis
The stoichiometry for the binding of chartreusin to DNA was obtained using the method of continuous variation (18) . The concentrations of chartreusin and DNA were each varied, while the sum of the concentrations was kept constant at 30 mM. Varying volumes of equally concentrated stock solutions of chartreusin and DNA were mixed to give a mole fraction of ligand ranging from 0 to 0.6. The difference in absorbance (DA 420 nm ) was plotted against the mole fraction of drug.
Isothermal titration calorimetry
Experiments were carried out at different temperatures (between 20 and 35°C) using a Microcal MCS-ITC calorimeter (Microcal Inc., Northampton, MA). The Origin software (Microcal) was used for data acquisition and analysis. In a typical experiment, 1.34 ml of a 0.75 mM (bp) DNA in 10 mM cacodylate buffer (pH 7.0) containing 8 mM NaCl and 0.1 mM EDTA ([Na + ] = 18 mM) was titrated using a 50 mM chartreusin solution in the same buffer (15±25 injections of 10 ml each), using a 250 ml syringe rotating at 400 r.p.m. The injection time was 25 s and the delay between injections was 2.5 min. The peaks produced during titration were converted to heat output per injection by integration and correction for the cell volume and sample concentration.
Determination of the binding enthalpy by isothermal titration calorimetry
Binding enthalpies for chartreusin were determined from the heats of reaction obtained after each injection using a`modelfree ITC' protocol (19, 20) to obtain multiple estimates of DH 0 without any ®tting bias. This protocol, which uses a high DNA concentration, ensures that all the titrated drug is effectively bound after each addition. The dilution heats, determined by injecting drug solution into the reaction cell loaded with buffer alone, were subtracted from the DH value determined for titration into DNA to render a corrected value for the binding-induced enthalpy change DH b (19) .
Heat capacity measurements
Data obtained from ITC experiments were used to measure DCp, the change in heat capacity. DCp was measured as the temperature dependence of the binding enthalpy according to the relationship:
DNA UV melting studies
Pro®les of absorbance at 260 nm versus temperature were measured between 25 and 98°C, at a heating rate of 0.5°C/min, in the presence of different concentrations of NaCl in 10 mM cacodylate buffer (pH 7.0) and saturating concentrations of chartreusin, using a Shimadzu UV-2101PC spectrophotometer equipped with a Shimadzu SPR-8 temperature controller.
Differential scanning calorimetry
Differential scanning calorimetry (DSC) measurements were performed using a Microcal MC-2 Scanning Calorimeter (Microcal Inc.). About 2 ml of a 0.56 mM DNA solution in 10 mM cacodylate buffer (pH 7.0) containing 8 mM NaCl and 0.1 mM EDTA ([Na + ] = 18 mM) were used for DSC experiments. A heating rate of 0.5°C/min was used. DSC scans were corrected by subtraction of a buffer±buffer baseline, normalized to the concentration of DNA (in base pairs) and further baseline corrected. Data acquisition and analysis were performed with the graphics software Origin (Microcal Inc.).
Determination of binding constant by DNA UV melting analysis
The DNA melting temperatures (T m ) determined by UV melting in the presence of saturating amounts of chartreusin and in its absence (also determined by UV melting) were used to calculate the binding constant to salmon DNA at the DNA melting temperature (K Tm ), using the equation derived by Crothers (21):
where T m 0 is the UV melting temperature of salmon testes DNA alone, T m is the melting temperature in the presence of saturating amounts of the drug, DH wc is the enthalpy of DNA melting obtained by DSC, R is the gas constant, K Tm is the drug binding constant at T m , a is the free drug activity, which is estimated by one half of the total chartreusin concentration, and n is the size of the drug-binding site, determined by continuous variation analysis.
The calculated apparent binding constant at T m can be extrapolated to a reference temperature using the standard relationship:
where K obs is the DNA binding constant of the drug at the reference temperature T (Kelvin) and DH b the binding enthalpy, which we determined directly by ITC at the reference temperature.
The experimental K obs , calculated at 20°C, and the binding enthalpy for chartreusin binding to DNA permitted the obtention of complete thermodynamic pro®les. Free energies were obtained from the standard relation DG 0 = ±RT lnK obs and the entropy evaluated using the standard thermodynamic relationship DS 0 = (DG 0 ± DH 0 )/T.
Analysis of the salt dependence of the binding constant
The effects of different NaCl concentrations upon the binding constant of chartreusin was calculated from the spectrophotometric UV melting pro®les, as described above, and used to determine the ionic strength dependence of the equilibrium binding constants, at 20°C, according to the polyelectrolyte theory of Record et al. (22) . The observed linear dependence is described by the relationship:
where y is the fraction of sodium counterion associated per DNA phosphate (y = 0.88 for B-DNA) and Z the apparent charge of the drug. Moreover, the Zy value was used to evaluate the polyelectrolyte contribution to the free energy of binding to salmon testes DNA using the relationship (22):
and the DG pe obtained (Table 1 ) was used to calculate DG t , thè non-polyelectrolyte contribution to binding' (23), using the following equation:
RESULTS AND DISCUSSION
The method of continuous variation was used to obtain the stoichiometry of the chartreusin±DNA interaction at 25 T 1°C. The intersection of least squares ®tted lines at X = 0.224 ( Figure 2A shows representative primary data from the calorimetric (ITC) titration of chartreusin into salmon testes DNA at 30°C. Figure 2B and C displays the distribution of binding enthalpy estimates obtained at four temperatures in the 20±35°C range. These distributions, which are essentially Gaussian, represent experimental error in the measurements rather than any site heterogeneity. Enthalpies were obtained from three independent titrations at each temperature and the different values averaged ( Table 1) .
The temperature-dependent differences in the binding enthalpy of chartreusin were used to calculate changes in heat capacity (DCp) measured as the slope of a plot of DH versus temperature (Fig. 3 and Table 1 ). The observed DCp (±391 T 37 cal/mol K) is clearly higher than that for other intercalators such as ethidium bromide (DCp = ±139 cal/mol K) or the charged multivalent intercalator daunorubicin (DCp = ±160 cal/mol K) (19) , but it is close to the DCp of ±375 cal/mol K determined for actinomycin D (19) , which is also an uncharged multivalent intercalator (24) .
The T m of DNA was 74.4°C (in 18 mM total Na + ), while in the presence of saturating concentrations of chartreusin the melting temperature rose to 78.0°C. The enthalpy of the DNA melting, determined by differential scanning calorimetry, was DH wc = 8.8 T 0.2 kcal/mol bp (Fig. 4) . DNA UV melting analyses and the DH b measured by ITC were used to calculate the binding constant for the chartreusin±DNA interaction at 20°C in the presence of 18 mM ®nal Na + by application of equations 1 and 2 ( Table 2) . Using this method, we calculated K obs without assuming that DH b was constant with temperature, as is usually adopted when the constant is derived from DSC studies only. Our ITC results demonstrate that this is not the case for the chartreusin binding to DNA (Fig. 3) . Moreover, the relatively high concentration of DNA we used in the`model-free ITC' protocol (20) ensured that all the added drug was bound to the nucleic acid, thereby there was no interference in the determination of DH b due to drug self-association (19, 20) .
The experimental calculation of the binding constant and the binding enthalpy for chartreusin allowed us to obtain complete thermodynamic pro®les evaluated at 20°C (Table 3) . The favorable free energy of chartreusin binding to DNA (DG = ±7.4 kcal/mol at 20°C) is derived from a large negative enthalpic contribution (DH b = ±7.1 kcal/mol).
Previous attempts to determine DNA binding constants for chartreusin did not render reliable quantitative results (11) , re¯ecting the dif®culties associated with the experimental measurements (11, 25) . The uncertainties in the quantitative Table 1 for further details. K Tm , the drug binding constant at T m , and K obs , the drug binding constant determined at 20°C, were calculated using equations 2 and 3 as described in the main text. For application of equation 3, the chartreusin binding enthalpy, DH b at 20°C (Table 1) , was used. a T m 0 (°C) is the melting temperature of 20 mM DNA in the absence of drug. T m (°C) is the melting temperature of 20 mM DNA in the presence of 10 mM chartreusin (saturating conditions).
evaluation of the chartreusin binding constant could be attributable to problems in ®tting the experimental spectroscopic data to mathematical models used in binding analysis (11) . In our study, we have obtained a more direct estimate of the binding constant, without recourse to model-dependent curve ®tting.
The DNA binding constant of chartreusin was also determined at different salt concentrations using the UV melting temperatures of drug±DNA complexes ( Table 2 ). The binding constant for chartreusin changed only slightly with the different salt concentrations. Figure 5A shows the dependence of the binding constant on the salt concentration as determined by UV melting studies. These results indicated that chartreusin binding to DNA was accompanied by a rather low counterion release. The salt-dependent changes in binding constants were used, according to the polyelectrolyte theory (22), to calculate the`actual' charge of a ligand and the salt dependence of the binding constant using equations 5 and 6. The slope of the double logarithmic Record's plot in Figure 5A (SK values in Table 3 ) is equivalent to the number of counterions released upon drug binding. We found that only 0.13 counterions were released from DNA upon drug binding, which corresponds to a calculated apparent change (Z = 0.15) consistent with the absence of any net charge in chartreusin (Fig. 1A) .
From the dependence of the binding constant on salt concentration, the observed binding free energy was partitioned in the non-polyelectrolyte (DG t ) and polyelectrolyte (DG pe ) components using equation 6 (Table 3) . A DG t of ±7.1 kcal/mol indicates that the non-electrolyte component of binding is fundamental in the stabilization of the chartreusin complex with DNA. As a comparison, we used equation 5 to calculate DG pe at 200 mM Na + (DG pe = ±0.12 kcal/mol). The polyelectrolyte contribution for chartreusin binding is close to the values determined, at this ionic strength, for the intercalation of the uncharged actinomycin or hydroxyrubicin molecules (23, 24) . Consequently, the slight salt dependence of chartreusin binding to DNA should arise from the ion release due to increased phosphate spacing that results from intercalation (24) .
The binding reaction is driven by the enthalpy contribution, with a rather small entropy contribution (Table 3) . The unfavorable entropic cost of DNA±drug complex formation seems to be partially compensated for by the release of counterions, as wells as the presence of the uncharged disaccharide moiety in the minor groove of DNA. The chartreusin disaccharide occupies the minor groove of the helix (17) providing some discrimination for the nucleotide on the 5¢-side of the intercalation site (15) . It may displace water molecules, providing a positive entropic term that is likely remedied by the negative entropy from the decreased¯exi-bility of DNA. DH b became more negative as the temperature increased (Table 1) , which was accompanied by changes in DS and an associated enthalpy± entropy compensation (26) , thus rendering small changes in DG and K obs (Tables 2 and 3 ). The peculiar disaccharide of chartreusin is not only important for the total strength of binding. Changes in the sugar of some useful antitumor drugs are considered to lead to alterations in their biological activity through mechanisms that are not always related to DNA binding (8, 27) .
In a previous paragraph, we analyzed the polyelectrolyte contributions to the binding free energies (DG pe ). At least four other components are considered to parse (dissect) the drug binding energies of the binding free energy into contributions Figure 5A . DG pe and DG t are the polyelectrolyte and nonpolyelectrolyte contributions to the binding free energy (DG pe = SK RT ln[Na + ]) evaluated at 18 mM Na + . DH b was determined by ITC at 20°C (see Table 1 ). from the processes that lead to complex formation (2, 3) . Hence, the observed binding free energy (DG obs ) would contain contributions from ®ve terms:
where DG conf is the free energy contribution from the conformational changes in DNA and drug upon complex formation, DG r + t is the free energy cost resulting from losses in rotational and translational degrees of freedom upon complex formation, DG hyd is the free energy for the hydrophobic transfer of a drug from solution into the DNA binding site and DG mol is the free energy contribution from DNA±drug interactions. We shall discuss the parsing of the free energy (DG obs ) in the context of the structural characteristics of chartreusin and the binding to DNA, to help in the dissection of the free energy. The formation of an intercalation complex would require the unstacking of adjacent bases and lengthening of the DNA helix. In general, the intercalation of a drug in DNA would involve an unfavorable DG conf term (Fig. 5B) . The unwinding of the double helix after intercalation of elsamicin A, which bears the same chartarin chromophore as chartreusin, has been measured experimentally (28) . However, the effect of binding the disaccharide moiety of chartreusin in the minor groove is less obvious. A negligible DG conf (DG conf = 0) has been contemplated in Hoechst 33258 binding into the minor groove of DNA (29) . The values for DG conf and DG r + t used in Figure 5B may be considered extreme (19, 20) . The magnitude used for DG r + t in equation 7 was taken from those in the bibliography about intercalating reactions (3, 5) .
The DH b estimated by ITC at different temperatures ( Fig. 3 and Table 1 ) were used to experimentally determine DCp for chartreusin, which can be used to determine DG hyd using the relationship DG hyd = 80 DCp, with an~25% error, providing insights into the hydrophobic contribution to binding (30) . The experimental measurement of the heat capacity change for chartreusin shows that the free energy contribution for the hydrophobic transfer process is large and favorable (negative), a consequence of the several hydration contributions involved in the formation of an intercalative complex. Molecular dynamics calculations have been used to study speci®c drug±DNA interactions and the role of the solvent water molecules in the drug±DNA complex of the chartarincontaining molecule elsamicin A (17) . These investigations showed that the chromophore shared by elsamicin A and chartreusin is largely buried inside the DNA intercalation site and the solvent-accessible surface is rather small (17) . Accessibility to solvent has been correlated with the magnitude of DCp and the hydrophobic component of binding (19) . From a quantitative point of view, the largely buried chartarin chromophore should render high DCp values, as experimentally observed (Table 1) . Since the computed calculations were on the intercalated chromophore, we cannot use them to analyze the participation of the disaccharide moiety in the hydrophobic component of chartreusin binding to DNA.
In general, it is considered that the somewhat large contribution of the hydrophobic transfer (DG hyd ) might suf®ce to overwhelm other unfavorable contributions from changes in conformation and the entropic cost of forming a bimolecular complex (3, 5) , thus achieving the DG obs and K obs observed.
We found that considering DG hyd to be about ±23 kcal/mol [which is the lower limit of the estimate derived from the relation DG hyd = 80 (T 10) DCp] was committing to obtaining a negative value for DG mol , thus accounting for the different non-covalent interactions that are formed in a drug±DNA complex (Fig. 5B) . Using a DG hyd of ±31 kcal/mol would generate the cumbersome participation of positive (unfavorable) interactions in a multivalent intercalation. In the parsing of free energy (Fig. 5B ) DG mol is assigned following an approach in which the sum of the other contributions discussed above is considered. The resulting value is subtracted from the experimental DG obs (19) . Therefore, DG mol is the contribution of all molecular interactions not considered in the DG hyd and DG pe terms, such as, for example, van der Waals interactions.
Although a parsing exercise has recognized limitations (19, 20) , it was worth performing because chartreusin is an example of a multivalent molecule consisting of an intercalating chromophore bound to a disaccharide moiety. Therefore, the data obtained may be useful in the rational design of polyintercalating antitumor drugs containing a saccharide or other moieties lying in the minor groove. Sugar moieties have been shown to be an essential component of some antibiotics for their topoisomerase poisoning activity and antitumor ef®cacy (27) and might play a key role in the high activity of chartreusin against topoisomerase II (16) . It would be interesting to understand whether an uncharged carbohydrate moiety in multivalent intercalators is compatible with strong binding to DNA, as observed here, while the presence, or absence, of protonatable amino groups in the carbohydrate moiety could also participate in the ability of a polyfunctional drug to overcome its processing by multidrug resistance systems (31) .
